[Inhalative immunostimulation in patients with chronic bronchitis].
80 patients with chronic bronchitis were treated inhalatively for a time of 3 weeks with a polyvalent bacterial lysate (IRS 19) or with placebo. The study was carried out in a double-blind fashion. Treatment with IRS 19 resulted in improved bronchoscopic findings compared with the pretherapy findings. Patients with bronchial hyperreactivity showed in the IRS 19 group small improvement of the hyperreactivity. In this group the contents of IgG in the BAL fluid showed a significant reduction, the other parameters were unchanged.
Kaspar
P
P
Klinik Bad Reichenhall der LVA Niederbayern/Oberpfalz, Fachklinik für Erkrankungen der Atmungsorgane.
Petro
W
W
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000280:Administration, Inhalation; D000403:Airway Resistance / Q000187:drug effects; D001428:Bacterial Vaccines / Q000008:administration & dosage*; D001991:Bronchitis / Q000276:immunology / Q000628:therapy*; D001992:Bronchoalveolar Lavage Fluid / Q000032:analysis; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D011897:Random Allocation
D000276:Adjuvants, Immunologic; D001428:Bacterial Vaccines; C046290:IRS 19 vaccine; D007070:Immunoglobulin A; D007074:Immunoglobulin G
Inhalative Immunstimulation bei Patienten mit chronischer Bronchitits.